Tarek Mekhail, MD
Hematology & Oncology · Orlando, FLNPI 1447214911
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,781,443 of the $2,240,763 with a category attached, or 79.5%. 39 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,648 payments — averaging $1359.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$632K
- E.r. Squibb & Sons, L.L.C.$458K
- Lilly USA, LLC$244K
- Takeda Pharmaceuticals U.S.A., Inc.$202K
- Amgen$127K
- Daiichi Sankyo Inc.$121K
- plus $458K from 33 others
Across 757 payments — averaging $11,907 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3M
- Pfizer$1.3M
- AstraZeneca$807K
- Amgen$695K
- Takeda Pharmaceuticals U.S.A., Inc.$646K
- Genmab U.S., Inc.$424K
- plus $2.1M from 16 others
What the payments were for
- Consulting fees$205,8759%
- Speaking & faculty fees$1,781,44380%
- Travel & lodging$222,78210%
- Food & beverage$28,1031%
- Education$2,5610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 380 | $631,885 |
| E.r. Squibb & Sons, L.L.C. | 265 | $457,536 |
| Lilly USA, LLC | 253 | $243,595 |
| Takeda Pharmaceuticals U.S.A., Inc. | 112 | $202,215 |
| Amgen | 135 | $126,551 |
| Daiichi Sankyo Inc. | 112 | $121,343 |
| Genentech USA, Inc. | 79 | $115,613 |
| Regeneron Healthcare Solutions, Inc. | 104 | $105,050 |
| Merck | 55 | $61,795 |
| Mirati Therapeutics, Inc. | 16 | $30,324 |
| Novartis | 20 | $29,596 |
| Coherus Oncology, Inc. | 25 | $26,345 |
| Boehringer Ingelheim | 18 | $24,102 |
| Sanofi | 8 | $11,980 |
| F. Hoffmann-la Roche AG | 8 | $8,516 |
| Gilead | 11 | $6,755 |
| Pfizer | 2 | $5,008 |
| Eli Lilly | 2 | $4,950 |
| Janssen Scientific Affairs, LLC | 5 | $4,430 |
| Exelixis Inc. | 2 | $4,080 |
| Novocure Inc. | 1 | $2,600 |
| Fresenius Kabi USA, LLC | 1 | $2,500 |
| Johnson & Johnson | 6 | $2,425 |
| Catalyst Pharmaceuticals, Inc. | 2 | $2,350 |
| Eisai Inc. | 1 | $2,040 |
| Bristol Myers Squibb(2 entities) | 3 | $1,548 |
| AbbVie | 1 | $1,500 |
| Celltrion, Inc. | 1 | $1,200 |
| GSK | 1 | $800 |
| Blueprint Medicines Corporation | 1 | $743 |
| EMD Serono, Inc. | 1 | $500 |
| Delcath Systems | 1 | $219 |
| Seagen Inc. | 10 | $153 |
| Bayer | 1 | $125 |
| Astellas Pharma US Inc | 1 | $100 |
| Incyte Corporation | 1 | $100 |
| Caris MPI, Inc. | 1 | $93 |
| Genmab U.S., Inc. | 1 | $84 |
| Beigene USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$443,309
- TAGRISSO$293,841
- IMFINZI$185,722
- RETEVMO$131,900
- Enhertu$118,903
- LIBTAYO$115,848
- TECENTRIQ$98,957
- LUMAKRAS$76,536
- ALUNBRIG$73,259
- KEYTRUDA$52,284
- EXKIVITY$51,420
- DATROWAY$33,820
- KRAZATI$30,324
- IMDELLTRA (AMG 757)$18,557
- ALIMTA$17,285
- CYRAMZA$14,456
- LOQTORZI$13,721
- MEKINIST$10,641
- GILOTRIF$8,040
- Alecensa$7,472
How this compares
$2,240,763 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 38 | $629,320 |
| RevlimidLenalidomide | 36 | $543,923 |
| Lenalidomide | 31 | $442,132 |
| RozlytrekEntrectinib | 12 | $234,257 |
| MekinistTrametinib Dimethyl Sulfoxide | 15 | $210,259 |
| AlecensaAlectinib Hcl | 11 | $204,956 |
| CalquenceAcalabrutinib Maleate | 11 | $158,906 |
| EliquisApixaban | 34 | $20,260 |
| XareltoRivaroxaban | 15 | $14,112 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 89 | $3,093 |
| Ondansetron Hcl | 106 | $2,875 |
| Prochlorperazine Maleate | 94 | $1,272 |
| SynthroidLevothyroxine Sodium | 14 | $969 |
| Oxycodone Hcl | 44 | $822 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $631,885 | $788,22649 claims |
| Bristol Myers SquibbRevlimid | $1,548 | $543,92336 claims |
| Genentech USA, Inc.Rozlytrek, Alecensa | $115,613 | $439,21323 claims |
| NovartisMekinist | $29,596 | $210,25915 claims |
| PfizerEliquis | $5,008 | $20,26034 claims |
| Johnson & JohnsonXarelto | $2,425 | $14,11215 claims |
| AbbVieSynthroid | $1,500 | $96914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Orlando
- Mark SocinskiOrlando$2.4M
- Daniel LandauOrlando$1.8M
- Shahram MoriOrlando$952K
- Sajeve ThomasOrlando$639K
- Nikita ShahOrlando$470K
- Martin DietrichRockledge$6.2M
- Edgardo SantosFort Lauderdale$2M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.